Combination of G-CSF, Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Multiple Myeloma
Status:
Unknown status
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Bortezomib may stop the growth of myeloma cells by blocking proteasome activity.
Cyclophosphamide and dexamethasone may work in different ways to stop the growth of myeloma
cells by stopping them from dividing or by killing the cells. Granulocyte Clone Stimulating
Factor (G-CSF) possesses the ability to mobilize the plasma cells to detach from myeloma
niche, so as to promote drug sensitivity.
PURPOSE: This phase Ⅱ trial is to study how well combination of G-CSF, bortezomib,
cyclophosphamide and dexamethasone works in treating patients with multiple myeloma.